Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II comparison of MeMuRu-OKA versus Priorix + Varilrix as second-dose MMRV vaccination in previously vaccinated healthy children
2005-005825-75Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2006
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in measles, mumps, rubella and 1 more comparing MeMuRu-OKA with Priorix + Varilrix (2 arms). Primary endpoint: Geometric mean titre ratios for measles, mumps, rubella and varicella. Started Mar 2006; status: completed.
02
Drugs
GSK208136measles, mumps and rubella vaccine (live)varicella virus vaccine live
03
Conditions
measlesmumpsrubellachickenpox
Beyond the preview
Go deeper on 2005-005825-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005825-75.